The Food & Drug Administration (FDA) has given ray of hope to Sarepta Therapeutics by agreeing to consider its experimental drug for Duchenne muscular dystrophy for accelerated approval. Sarept’s eteplirsen is a new intravenous drug known to stabilize the symptoms of a rare and fatal form of muscular dystrophy known as Duchenne. Expressing confidence in positive FDA decision, Sarepta … [Read more...]
You are here: Home / Archives for Sarpeta drug